PA
CAPR icon

Profund Advisors’s Capricor Therapeutics CAPR Stock Holding History

Profund Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$734K Buy
30,482
+2,524
+9% +$76.5K 0.02% 425
2026
Q1 		$850K Buy
+27,958
New +$745K 0.03% 393
2025
Q3 		– Sell
-10,241
Closed -$102K – 1059
2025
Q2 		$102K Sell
10,241
-6,867
-40% -$72.5K ﹤0.01% 964
2025
Q1 		$162K Sell
17,108
-6,899
-29% -$95.8K 0.01% 926
2024
Q4 		$331K Buy
+24,007
New +$421K 0.01% 713

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Profund Advisors's CAPR Position: Q2 2026 in Review

Profund Advisors increased its Capricor Therapeutics (CAPR) stake by 9% in Q2 2026, buying an estimated $76.5K and bringing the position to 30,482 shares worth $734K. The position accounts for 0.02% of the portfolio, ranked #425.

Profund Advisors first reported a position in CAPR in Q4 2024 and has held it in 5 quarters since. The position peaked at $850K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Profund Advisors held 30,482 shares of Capricor Therapeutics worth $734K as of Q2 2026.
  • Profund Advisors bought 2,524 Capricor Therapeutics shares in Q2 2026, an estimated $76.5K.
  • Capricor Therapeutics made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #425 holding.
  • Profund Advisors first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Profund Advisors's Capricor Therapeutics position peaked at $850K in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.